{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:31:46Z","timestamp":1784395906040,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1136\/ijgc-2023-004533","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T12:40:17Z","timestamp":1693399217000},"page":"1572-1579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Major determinants of survival in recurrent endometrial cancer\u2014the role of secondary cytoreductive surgery: a multicenter study"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4954-719X","authenticated-orcid":false,"given":"Virginia","family":"Vargiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3126-9400","authenticated-orcid":false,"given":"Andrea","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-5663","authenticated-orcid":false,"given":"Vito Andrea","family":"Capozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gio\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7848-0329","authenticated-orcid":false,"given":"Stefano","family":"Restaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-1063","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-7284","authenticated-orcid":false,"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004533_bb0010","year":"2022","journal-title":"Uterine cancer \u2014 cancer STAT facts, National Cancer Institute, surveillance, epidemiology and end results program"},{"key":"10.1136\/ijgc-2023-004533_bb0015","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004533_bb0020","first-page":"179","article-title":"Factors predicting recurrent endometrial cancer","volume":"5","author":"Huijgens","year":"2013","journal-title":"Facts Views Vis Obgyn"},{"key":"10.1136\/ijgc-2023-004533_bb0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2016.10.025","article-title":"Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO consensus conference risk groups: results from the FRANCOGYN study group","volume":"144","author":"Bendifallah","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ijgc-2019-000822","article-title":"Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment","volume":"30","author":"Legge","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0035","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/IGC.0000000000001296","article-title":"A proposal for a classification for recurrent endometrial cancer: analysis of a French multicenter database from the FRANCOGYN study group","volume":"28","author":"Bricou","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0040","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","article-title":"Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--a pooled analysis of PORTEC 1 and 2 trials","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0045","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s43032-021-00565-8","article-title":"The prediction of recurrence in low-risk endometrial cancer: is it time for a paradigm shift in adjuvant therapy?","volume":"29","author":"Laban","year":"2022","journal-title":"Reprod Sci"},{"key":"10.1136\/ijgc-2023-004533_bb0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0090-8258(84)90063-5","article-title":"Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients","volume":"17","author":"Aalders","year":"1984","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2006.02.011","article-title":"Follow-up after primary therapy for endometrial cancer: a systematic review","volume":"101","author":"Fung-Kee-Fung","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0060","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejso.2011.10.011","article-title":"Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors","volume":"38","author":"Ben Arie","year":"2012","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2012.12.020","article-title":"Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma","volume":"129","author":"Kilgore","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0070","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1634\/theoncologist.2010-0091","article-title":"Treatment for advanced and recurrent endometrial carcinoma: combined modalities","volume":"15","author":"Rauh-Hain","year":"2010","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2023-004533_bb0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ygyno.2006.03.011","article-title":"Salvage cytoreductive surgery for recurrent endometrial cancer","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0080","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s10147-019-01469-z","article-title":"Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer","volume":"24","author":"Shikama","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ygyno.2021.05.020","article-title":"Non-exenterative surgical management of recurrent endometrial carcinoma","volume":"162","author":"Moukarzel","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174176","article-title":"Recurrent endometrial cancer: which is the best treatment? Systematic review of the literature","volume":"14","author":"Restaino","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004533_bb0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/gyno.1996.0040","article-title":"Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration","volume":"60","author":"Morris","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/gyno.1999.5536","article-title":"Pelvic exenteration for recurrent endometrial cancer","volume":"75","author":"Barakat","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0110","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004533_bb0115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ygyno.2019.09.020","article-title":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: still getting any benefit? A case-control study","volume":"155","author":"Marchetti","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/gyno.1998.5017","article-title":"Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma","volume":"70","author":"Scarabelli","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0125","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/IGC.0000000000000543","article-title":"Salvage cytoreductive surgery for recurrent endometrial cancer","volume":"25","author":"Turan","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0130","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1245\/s10434-015-4504-5","article-title":"Surgical treatment of recurrent endometrial cancer: time for a paradigm shift","volume":"22","author":"Papadia","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-135","article-title":"Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study","volume":"14","author":"Ren","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cncr.11868","article-title":"Surgical treatment of recurrent endometrial carcinoma","volume":"100","author":"Campagnutta","year":"2004","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0145","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2006.01.007","article-title":"Surgical resection of recurrent endometrial carcinoma","volume":"102","author":"Awtrey","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ygyno.2010.04.005","article-title":"Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis","volume":"118","author":"Barlin","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.08.014","article-title":"Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival?","volume":"151","author":"Tseng","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0160","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1245\/s10434-020-09226-7","article-title":"The role of secondary cytoreductive surgery in recurrent ovarian cancer: a systematic review and meta-analysis","volume":"28","author":"Marchetti","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004533_bb0165","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/ijgc-2021-003017","article-title":"Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-En9\/LEAP-001","volume":"32","author":"Marth","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004533_bb0175","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004533_bb0180","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401716X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401716X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:28:26Z","timestamp":1753234106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2401716X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1048891X2401716X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004533","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Major determinants of survival in recurrent endometrial cancer\u2014the role of secondary cytoreductive surgery: a multicenter study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}